射血分数降低心衰合并中枢性睡眠呼吸暂停的治疗进展:聚焦治疗生理学(第2部分)
中枢性睡眠呼吸暂停/潮式呼吸(CSA/HCSB)在射血分数降低心衰(HFrEF)患者中常见,可导致交感神经过度激活、反复住院和过早死亡。氧气或气道正压治疗可降低交感活性,但两项最大RCT(CPAP和ASV)主要终点为阴性且死亡率增加;单侧膈神经刺激的RCT显示改善CSA及相关结局,但缺乏长期死亡率证据。NIH已资助低流量氧疗的3期RCT。
要点
- CSA/HCSB在HFrEF中常见,与交感激活、住院和死亡相关。
- CPAP和ASV的大型RCT主要终点阴性且死亡率增加,但存在缺陷。
- 单侧膈神经刺激改善CSA、觉醒、嗜睡和生活质量,但缺长期死亡率数据。
核心结论
- CSA/HCSB在HFrEF中具有重要病理生理意义,但现有PAP治疗的大型RCT主要终点阴性且死亡率增加,需识别表型以个体化治疗。
研究设计与样本
- 综述性文章,总结HFrEF合并CSA/HCSB的治疗性RCT证据及正在进行的试验。
主要发现
- 氧气或PAP治疗降低CSA/HCSB时可显著降低交感活性。
- CPAP和ASV两项最大RCT主要终点阴性且均与死亡率增加相关。
- 单侧膈神经刺激的RCT显示改善CSA、减少觉醒、改善嗜睡和生活质量。
- NIH资助的低流量氧疗vs假治疗的3期RCT正在进行,复合主要终点包括全因死亡和心衰恶化住院。
临床怎么用
- 对HFrEF合并CSA/HCSB患者,应识别表型以指导治疗选择。
- 现有证据不支持常规使用CPAP或ASV治疗CSA/HCSB以改善主要结局。
- 单侧膈神经刺激可改善CSA相关症状,但长期死亡率获益未证实。
局限性
- 两项大型PAP RCT存在显著缺陷,结果可信度存疑。
- 单侧膈神经刺激缺乏长期死亡率试验证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Central sleep apnea/Hunter-Cheyne-Stokes breathing (CSA/HCSB) is prevalent in patients with heart failure with reduced ejection fraction (HFrEF). The acute pathobiologic consequences of CSA/HSCB eventually lead to sustained sympathetic overactivity, repeated hospitalization, and premature mortality. A few randomized controlled trials (RCTs) have shown statistically significant and clinically important reduction in sympathetic activity when CSA/HCSB is attenuated by oxygen or PAP therapy. Yet, the two largest PAP RCTs in patients with HFrEF, one with CPAP and the other with adaptive servoventilation (ASV), were negative with respect to their primary outcomes, and both were associated with excess mortality. However, both trials suffered from significant deficiencies, casting doubt on their results. A second RCT evaluating an ASV device with an advanced algorithm is ongoing. A new modality of therapy, unilateral phrenic nerve stimulation, has undergone an RCT that demonstrated an improvement in CSA that was associated with a reduction in arousals, improvement in sleepiness, and improvement in quality of life. However, a long-term mortality trial has not been performed with this modality. Most recently, the National Institutes of Health has funded a long-term, phase 3 RCT of low-flow oxygen vs sham for the treatment of CSA/HCSB in HFrEF. The composite primary outcome includes all-cause mortality and hospitalization for worsening HF. In this article, we focus on various therapeutic options for the treatment of CSA/HCSB and, when appropriate, emphasize the importance of identifying CSA/HCSB phenotypes to tailor treatment.
引用
- Javaheri S, Brown LK, Khayat RN, et al. Update on Apneas of Heart Failure With Reduced Ejection Fraction: Emphasis on the Physiology of Treatment: Part 2: Central Sleep Apnea. Chest. 2020. PMID: 31958442. doi:10.1016/j.chest.2019.12.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。